John Maslowski | CEO
Fibrocell Science Inc
John Maslowski serves as Fibrocell’s President & Chief Executive Officer. Previously, he was SVP of Scientific Affairs, with oversight of R&D, clinical and regulatory affairs, and formerly was VP of Operations with responsibility for manufacturing and quality operations. Prior to Fibrocell, he held various positions at Wyeth Pharmaceuticals, Inc. (now Pfizer, Inc.), Merck & Co. and Teva. Mr. Maslowski earned a B.S. in Biology from Ursinus College and an M.S. in Biology from Villanova University.
Appearances:
Pharma Pricing & Market Access USA Day 2 @ 09:00
Assessing value frameworks for cellular and gene therapy products
- Understanding fundamental differences in gene and cellular therapies
- What preliminary requirements are needed to be met to satisfy CBER FDA
- Current work of Fibrocell and the ever growing field of cellular and gene therapies
Pharma Pricing & Market Access USA Day 2 @ 16:10
Closing Keynote: Assessing value frameworks for cellular and gene therapy and one off cure products
- Understanding the impact of one off cures
- What preliminary requirements are needed to be met to satisfy CBER FDA
- Current work of Fibrocell and the ever growing field of cellular and gene therapies
Organiser
